Fig 1.

Pharmacodynamic assessments of (A) serum phosphorus; (B) renal tubular reabsorption of phosphate (TmP/GFR); (C) serum 1,25(OH)₂D; and (D) serum bone‐specific alkaline phosphatase. Data are presented as mean ± standard deviation. Baseline data points are shown in black, endpoint of the dose interval data points are shown in green, and midpoint of the dose interval data points are shown in blue, with the exception of week 21 for 1,25(OH)₂D shown in blue, which is neither the mid‐ nor endpoint of the dose cycle. Assessments in mass units are available in Supplemental Fig. S2.